- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04378855
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY). (PROPHECY)
May 4, 2020 updated by: Gruppo Italiano Malattie EMatologiche dell'Adulto
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY): A GIMEMA Observational Registry for Italian MPN Patients
This study will ultimately aim at developing a GIMEMA platform for collecting HRQoL and symptom burden information on Italian patients with Philadelphia chromosome negative MPN.
The main objective of the protocol is to improve our understanding of the impact of the disease and various treatments on patients-wellbeing, symptom burden and daily functioning.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
576
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients with myeloproliferative neoplasms (MPN)
Description
Inclusion Criteria:
- Patients diagnosed with Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (pre-PMF, overt-PMF) and post-ET/post-PV Myelofibrosis (MF), (i.e. Philadelphia chromosome negative myeloproliferative neoplasm (MPN)) according to 2016 WHO classification.
- Known IPSS/IPSET/DIPSS risk score category at time of initial diagnosis of PV, ET and PMF, respectively.
- Initial diagnosis of MPN within one year before date of registration.
- Having a full baseline PRO Evaluation completed.
- Adult patients (≥ 18 years old).
- Written informed consent provided.
Exclusion Criteria:
- Having any kind of psychiatric disorder or major cognitive dysfunction problems hampering a self-reported evaluation.
- Not able to read and understand local language (i.e. Italian).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare HRQoL profiles of Philadelphia chromosome negative MPN patients with those of their peers in the general population
Time Frame: After 5 years from study entry
|
To detect a baseline difference of at least 4 points between MPN patients and their peers in the general population in any of the following primary scales of the EORTC QLQ-C30 questionnaire: fatigue, global QoL/health status, physical, emotional and role functioning (all ranging from 0 to 100 points).
|
After 5 years from study entry
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare HRQoL profiles of Philadelphia chromosome negative MPN patients with those of their peers in the general population
Time Frame: After 5 years from study entry
|
The same comparisons described for the primary endpoint will be performed on all other scales from EORTC QLQ-C30 questionnaire.
|
After 5 years from study entry
|
Compare HRQoL profiles of Philadelphia chromosome negative MPN patients with those of their peers in the general population
Time Frame: After 5 years from study entry
|
The same comparisons described for the primary endpoint will be performed on all other scales from FACIT-Fatigue questionnaire.
|
After 5 years from study entry
|
MPN patients' baseline profiles of self-reported HRQoL
Time Frame: After 5 years from study entry
|
To report MPN patients' baseline profiles of self-reported HRQoL and symptoms scores.
|
After 5 years from study entry
|
Prognostic value, on overall survival and other clinical outcomes, of baseline patients' self-reported fatigue
Time Frame: After 5 years from study entry
|
To investigate the prognostic value of baseline patients' self-reported fatigue from EORTC QLQ-C30
|
After 5 years from study entry
|
Prognostic value, on overall survival and other clinical outcomes, of baseline patients' self-reported HRQoL
Time Frame: After 5 years from study entry
|
To investigate the prognostic value of baseline patients' self-reported HRQoL
|
After 5 years from study entry
|
Relationship between pruritus and HRQoL.
Time Frame: After 5 years from study entry
|
To investigate the relationship between Pruritus as assessed by MPN-SAF TSS questionnaire and HRQoL.
|
After 5 years from study entry
|
Patterns over time of HRQoL
Time Frame: After 5 years from study entry
|
To estimate and compare patterns over time of HRQoL (outcome measures: EORTC QLQ-C30, FACIT-Fatigue, MPN-SAF TSS and FACIT-TS-G) of PT, EV and PMF patients.
|
After 5 years from study entry
|
Prognostic patient-based index
Time Frame: After 5 years from study entry
|
To devise a prognostic patient-based index.
|
After 5 years from study entry
|
Physicians' and patients' preferences for involvement in treatment decision-making
Time Frame: After 5 years from study entry
|
To assess physicians' and patients' preferences for involvement in treatment decision-making, as assessed by the CPS Questionnaire, across different risk groups and examine relationships between preferences for involvement and patient characteristics.
|
After 5 years from study entry
|
Relationship between self-reported satisfaction with care with other HRQoL outcomes.
Time Frame: After 5 years from study entry
|
To investigate the relationship, in MPN patients, between self-reported satisfaction with care as assessed by the FACIT-TS-G questionnaire and its relationship with other HRQoL outcomes.
|
After 5 years from study entry
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
May 1, 2020
Primary Completion (ANTICIPATED)
May 1, 2023
Study Completion (ANTICIPATED)
May 1, 2025
Study Registration Dates
First Submitted
April 28, 2020
First Submitted That Met QC Criteria
May 4, 2020
First Posted (ACTUAL)
May 7, 2020
Study Record Updates
Last Update Posted (ACTUAL)
May 7, 2020
Last Update Submitted That Met QC Criteria
May 4, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIMEMA QoL-MPN 0118
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloproliferative Neoplasm
-
Sociedad de Lucha Contra el Cáncer del EcuadorCompletedMyeloproliferative Disorders | Myeloproliferative Neoplasm | Myeloproliferative Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative Disease, Not ClassifiedEcuador
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedMyelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedUnited States
-
Astex Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmUnited States, Canada
-
ImmunoGen, Inc.Active, not recruitingBlastic Plasmacytoid Dendritic Cell Neoplasm | Myeloproliferative NeoplasmUnited States, Spain, Germany, Italy, France, United Kingdom
-
Fred Hutchinson Cancer CenterImmunoGen, Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute LeukemiaUnited States
-
BeiGeneRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative NeoplasmChina, United States, Australia, Spain, Korea, Republic of, New Zealand, Germany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
University of California, IrvineCompletedMyeloproliferative NeoplasmUnited States
-
Fondazione per la Ricerca Ospedale MaggioreCompletedMyeloproliferative NeoplasmItaly, United Kingdom, Germany, France, United States, Spain, Canada
Clinical Trials on Questionnaire
-
H. Lee Moffitt Cancer Center and Research InstituteSan Diego State University; University of Minnesota; University of ArizonaCompletedAnxiety | Psychological StressUnited States
-
Centre Hospitalier Universitaire de NiceCompletedGeneral Population | TDAH | Children Aged 5 to 18 YearsFrance
-
Imperial College LondonRoyal Marsden NHS Foundation Trust; University College London Hospitals; The... and other collaboratorsCompleted
-
Minneapolis Veterans Affairs Medical CenterUnited States Department of DefenseCompletedLower Limb Amputation Below Knee (Injury) | Lower Limb Amputation Above Knee (Injury)United States
-
NSABP Foundation IncNational Cancer Institute (NCI)Completed
-
Stanford UniversityRecruitingAstigmatism | Nearsightedness | FarsightednessUnited States
-
University of LiegeCompletedCritical Illness | Covid19 | Psychological Stress | FamilyBelgium
-
Imperial College Healthcare NHS TrustNot yet recruitingCervical Myelopathy
-
Rabin Medical CenterCompleted
-
National Taiwan University HospitalNational Taiwan UniversityUnknownComputerized Physician Order EntryTaiwan